Blue Owl Capital Holdings LP Invests $4.30 Million in LENZ Therapeutics, Inc. $LENZ
Blue Owl Capital Holdings LP has acquired a new stake in LENZ Therapeutics, Inc. (NASDAQ:LENZ), purchasing 756,722 shares valued at approximately $4.30 million. This investment represents about 2.41% of LENZ Therapeutics and 0.6% of Blue Owl's portfolio. Despite LENZ shares trading near their one-year low, institutional ownership remains significant at 54.32%, and analysts hold a "Moderate Buy" consensus with an average price target of $28.80.
LENZ Therapeutics (NASDAQ:LENZ) Stock Rating Upgraded by Zacks Research
Zacks Research has upgraded LENZ Therapeutics (NASDAQ:LENZ) from a "strong sell" to a "hold" rating, though other analysts remain divided, resulting in an overall "Moderate Buy" rating with an average price target of $28.80. The company's stock rose 2.8% to $4.73, while it reported better-than-expected quarterly results with a loss of $1.02 per share and revenue of $5.49 million, surpassing analyst estimates. Despite beating expectations, LENZ continues to post substantial losses, with analysts forecasting a full-year loss of $4.18 per share.
Earnings Release: Here's Why Analysts Cut Their LENZ Therapeutics, Inc. (NASDAQ:LENZ) Price Target To US$26.83
Analysts have cut LENZ Therapeutics, Inc.'s revenue estimates for 2026 and reduced their price target to US$26.83, despite lowering loss estimates. While the company beat revenue estimates in its latest report, future revenue is expected to decline significantly, underperforming the broader industry. This shift indicates increased pessimism regarding the company's intrinsic value.
Earnings Release: Here's Why Analysts Cut Their LENZ Therapeutics, Inc. (NASDAQ:LENZ) Price Target To US$26.83
Analysts have revised down their revenue estimates for LENZ Therapeutics, Inc. for 2026 to US$17.0m, a significant 21% decline, despite beating recent revenue estimates. Although loss estimates were reduced, the consensus price target for LENZ Therapeutics was cut by 16% to US$26.83, reflecting pessimism due to the revenue downgrade and expected underperformance compared to the broader industry. The wide range of analyst price targets suggests difficulty in accurately valuing the company's future.
Lenz stock drops as Bank of America downgrades (LENZ:NASDAQ)
Lenz Therapeutics' stock fell for the third straight day after Bank of America downgraded the company from Buy to Neutral. The downgrade was attributed to a slower-than-expected launch of its presbyopia therapy, VIZZ. Analyst Jason Gerberry also lowered his price target for LENZ.
BofA downgrades Lenz Therapeutics stock rating on slow launch
BofA Securities downgraded LENZ Therapeutics Inc. (NASDAQ:LENZ) from Buy to Neutral and cut its price target significantly, citing a slower-than-expected launch of its VIZZ presbyopia eye drops. Despite some positive financial results in Q2 2026, including a revenue beat, the firm expressed concerns about the company's cash burn and path to profitability, now valuing the stock primarily on its cash position. This downgrade comes amidst modest prescription-volume growth for VIZZ, leading BofA to reduce its near-term and peak sales forecasts.
LENZ Therapeutics, Inc. Stock 12‑Month Price Target Cut to $29.86, Implies 473% Upside
Analysts have revised the average 12-month price target for LENZ Therapeutics, Inc. (LENZ) stock down to $29.86 from $32, with individual forecasts ranging from $7 to $60 per share. Despite the cut, this new target still suggests a substantial 473% potential upside from its August 11 closing price. The consensus rating for LENZ remains a "Buy" among the 7 covering analysts.
Over 60% of LENZ’s VIZZ ePharmacy Patients Bought Multiple Packs
LENZ Therapeutics reported Q2 2026 total revenue of $5.5 million, with VIZZ product sales reaching $1.7 million from approximately 27,000 packs. The company highlighted strong early adoption for VIZZ, noting that over 60% of ePharmacy patients purchased multiple monthly packs, tracking to about five packs annually in early cohorts. LENZ also expanded its international presence with new agreements in Australia/New Zealand, Canada, Greater China, and Saudi Arabia, while reporting a net loss of $31.9 million for the quarter.
LENZ Therapeutics (NASDAQ:LENZ) Issues Earnings Results, Beats Estimates By $0.03 EPS
LENZ Therapeutics (NASDAQ:LENZ) reported its quarterly earnings, beating analyst estimates by $0.03 EPS with a loss of $1.02 per share and revenue of $5.49 million, significantly exceeding expectations. Despite commercial momentum and increased prescription sales, the company posted a $31.9 million net loss, and its stock declined by 2.8%. Analysts currently hold a "Hold" rating with an average price target of $29.80 for the stock.
Earnings call transcript: LENZ Therapeutics tops Q2 2026 forecasts as sales jump
LENZ Therapeutics exceeded Q2 2026 financial forecasts, reporting a narrower loss of $1.02 per share and revenue of $5.5 million, significantly beating analyst expectations. The positive results were driven by strong early adoption of its presbyopia eye drop, VIZZ, including a 45% month-over-month increase in July prescriptions, supported by new telehealth options and national TV advertising. The company emphasized VIZZ's high refill rates compared to competitors, its strong cash position, and plans for disciplined capital allocation to sustain growth and global expansion.
LENZ Therapeutics (LENZ) grows VIZZ sales but posts $31.9M Q2 loss
LENZ Therapeutics reported a Q2 2026 net loss of $31.9 million despite generating $5.5 million in total revenue, driven by VIZZ product sales and ex-U.S. licensing agreements. The company's net loss was primarily due to increased selling, general, and administrative expenses as it expanded commercial activities for its FDA-approved presbyopia eye drop, VIZZ. LENZ believes its current liquidity of $220.0 million will fund operations for at least 12 months as it continues to commercialize VIZZ and seek international partnerships.
LENZ Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
LENZ Therapeutics reported strong Q2 2026 financial results with $5.5 million in total revenue from VIZZ product sales and global license agreements. The company highlighted accelerating VIZZ prescription growth through its new telehealth channel and strong patient persistence, with over 60% of ePharmacy patients purchasing multiple monthly packs. LENZ also expanded its global commercialization strategy with new international partnerships and regulatory submissions for VIZZ.
LENZ’s VIZZ Launch Puts Presbyopia Sales Under The Microscope
LENZ Therapeutics (Nasdaq: LENZ) is set to report its Q2 2026 earnings on August 11th, with investors keenly focused on the commercial success of its presbyopia eye-drop, VIZZ (LNZ100). The company's stock has significantly underperformed the broader market, dropping around 83% over the past year, reflecting market concerns about execution risk and commercial adoption. The article details the bull and bear cases, highlighting the high-risk, high-optionality nature of LENZ as it navigates the competitive presbyopia market and aims to turn early prescription momentum into sustainable revenue and profitability.
LENZ Therapeutics to Report Second Quarter 2026 Financial Results and Recent Corporate Highlights on August 11, 2026
LENZ Therapeutics announced it will host a webcast on August 11, 2026, at 4:30 p.m. EDT to report its second quarter 2026 financial results and recent corporate highlights. The company is focused on the commercialization of VIZZ® (aceclidine ophthalmologic solution) 1.44%, an FDA-approved eye drop for presbyopia. A replay of the webcast will be available on the company's website.
LENZ Therapeutics Sets Webcast on Its FDA-Approved Eye Drop
LENZ Therapeutics announced it will host a webcast on August 11, 2026, to discuss its second-quarter 2026 financial results and recent corporate highlights. The webcast will feature discussions on VIZZ® (aceclidine ophthalmologic solution) 1.44%, the company's FDA-approved eye drop for presbyopia. The announcement follows a moderate positive market reaction to LENZ's previous earnings report.
LENZ Therapeutics to Report Second Quarter 2026 Financial Results and Recent Corporate Highlights on August 11, 2026
LENZ Therapeutics, Inc. announced it will host a webcast on August 11, 2026, at 4:30 p.m. EDT to report its second quarter 2026 financial results and recent corporate highlights. The pharmaceutical company, focused on commercializing VIZZ® (aceclidine ophthalmologic solution) 1.44% for presbyopia, will provide details for accessing the conference call and live webcast. A replay will be available on their website for 30 days.
LENZ Therapeutics Inc (LENZ) - Tradingkey Stock Score & Comprehensive Stock Analysis
This article provides a comprehensive stock analysis and "TradingKey Stock Score" for LENZ Therapeutics Inc (LENZ). It highlights the company's strong fundamentals, significant growth potential, and fair valuation within the Biotechnology & Medical Research industry. The analysis also covers institutional ownership, analyst ratings, and the company's product pipeline including LNZ100 and LNZ101 for presbyopia treatment.
LENZ Therapeutics Inc (LENZ) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of LENZ Therapeutics Inc (LENZ), listing its major shareholders and their proportions, such as RA Capital Management, LP (13.33%) and Fidelity Management & Research Company LLC (11.81%). It also categorizes shareholder types, including Investment Advisor (42.54%) and Venture Capital (33.60%), and provides institutional shareholding trends over several quarters. Additionally, the article lists ETFs with holdings in LENZ Therapeutics.
LENZ Therapeutics, Inc. Revenue Breakdown – NASDAQ:LENZ
This article provides a basic overview of LENZ Therapeutics, Inc. (NASDAQ: LENZ) on TradingView, focusing on accessing its financial data. It indicates the stock market status and directs users to various financial segments like statements, statistics, dividends, earnings, and segment performance. The content is primarily a navigation hub to financial information rather than an analysis itself.
LENZ Therapeutics (LENZ) 2024 Cantor Fitzgerald Global Healthcare Conference Summary
LENZ Therapeutics presented at the 2024 Cantor Fitzgerald Global Healthcare Conference, highlighting its once-daily eye drop for presbyopia. The company completed Phase III studies with an NDA filed, anticipating approval mid-next year and launch in the second half of 2025. The product demonstrated significant near vision improvement and high safety, targeting a $3 billion US market with a cash pay model and a strategic commercial launch plan.
LENZ|LENZ Therapeutics Inc|Price:5.030|Chg%:-0.310
LENZ Therapeutics Inc. is a pre-commercial stage biopharmaceutical company focused on developing aceclidine-based eye drops for presbyopia. Their lead product, LNZ100, is a once-daily eye drop that was evaluated in a Phase III study. The article also lists company executives, their shareholdings, and institutional ownership data for LENZ Therapeutics.
LENZ Therapeutics (LENZ) Q1 2026 earnings summary
LENZ Therapeutics reported Q1 2026 revenue of $1.9 million, primarily from VIZZ product sales, with over 46,000 prescriptions filled since launch. While new patient adoption is growing, it is below target, prompting expanded sales force and DTC campaigns. The company is actively pursuing international expansion and expects its cash reserves to fund operations through to positive operating cash flow.
Earnings Preview: LENZ Therapeutics, Inc. (LENZ) Q2 Earnings Expected to Decline
LENZ Therapeutics, Inc. (LENZ) is projected to report a decline in Q2 earnings and revenues year-over-year, with an expected quarterly loss of $1.21 per share and revenues of $2.21 million. Despite a recent upward revision in EPS estimates, the company's Earnings ESP of -8.04% and Zacks Rank of #4 make a positive earnings surprise unlikely. Investors should consider other factors beyond just a beat or miss when evaluating the stock.
LENZ Therapeutics (LENZ) Morgan Stanley 23rd Annual Global Healthcare Conference summary
LENZ Therapeutics (LENZ) presented at the Morgan Stanley 23rd Annual Global Healthcare Conference, highlighting the recent approval of its non-invasive ophthalmic drop for presbyopia, which uses aceclidine to restore near vision. The company's clinical trials demonstrated significant efficacy, with most patients achieving 20/40 vision or better within an hour and sustaining improvement for 10 hours without impacting distance vision. LENZ outlined a three-pillar commercial strategy focusing on doctor recommendations, consumer demand, and product access, with a targeted sales force and a direct-to-consumer campaign launching in Q1.
LENZ Therapeutics (LENZ) 2024 Cantor Fitzgerald Global Healthcare Conference Summary
LENZ Therapeutics presented at the 2024 Cantor Fitzgerald Global Healthcare Conference, highlighting its once-daily eye drop for presbyopia. The company completed Phase III studies, filed an NDA, and anticipates approval mid-next year for a launch in the second half of 2025. LENZ Therapeutics is targeting a significant market opportunity with a cash-pay model and a comprehensive commercial strategy, including educational campaigns and a substantial sales force.
LENZ Therapeutics (LENZ) Proxy filing Summary
LENZ Therapeutics (LENZ) has released a summary of its proxy filing, detailing plans for its virtual annual meeting on June 12, 2026. Stockholders will vote on electing three Class II directors and ratifying Ernst & Young LLP as the independent auditor for 2026. The board, composed of seven directors with six independent, recommends voting "FOR" all nominees and the auditor.
LENZ Therapeutics (LENZ) Leerink Global Healthcare Conference 2026 Summary
This article summarizes LENZ Therapeutics' presentation at the Leerink Global Healthcare Conference 2026, highlighting their presbyopia eye drop which offers rapid, long-lasting near vision improvement with minimal side effects. The product, using aceclidine, differentiates itself from competitors due to superior efficacy and duration. LENZ has seen strong market adoption since its October launch, with encouraging refill rates and increasing prescriptions from eye care professionals, indicating significant market opportunity.
We're Hopeful That LENZ Therapeutics (NASDAQ:LENZ) Will Use Its Cash Wisely
LENZ Therapeutics (NASDAQ:LENZ) had US$258m in cash by March 2026 and burned through US$87m in the last year, giving it a cash runway of about 3.0 years. While its cash burn increased significantly by 68% in the last year, analysts expect the company to reach cashflow breakeven before it runs out of cash. However, its cash burn of US$87m represents 53% of its US$164m market capitalization, indicating potential significant shareholder dilution should it need to raise more capital.
LENZ Therapeutics (LENZ) Stock Fair Value Moves Lower As Analysts Reset Growth Assumptions
Analysts have revised the fair value estimate for LENZ Therapeutics (LENZ) from US$53.71 to US$32.00, reflecting a reset in growth assumptions. While some analysts maintain a bullish stance on long-term prospects, others express caution due to execution risks and valuation concerns, leading to reduced price targets. The article highlights both bullish and bearish analyst perspectives and details how the fair value changes affect projected revenue growth, net profit margin, P/E multiple, and discount rate for LENZ Therapeutics.
LENZ Therapeutics Launches VIZZ Telehealth Prescribing Option for the Treatment of Presbyopia
LENZ Therapeutics has launched a new telehealth platform for VIZZ (aceclidine ophthalmic solution) 1.44%, an eye drop for presbyopia. This platform offers convenient online evaluations by independent licensed eyecare providers, e-pharmacy prescription fulfillment, and home delivery. The company aims to improve access to VIZZ for the estimated 128 million Americans with presbyopia, supporting this initiative with a national advertising campaign featuring Sarah Jessica Parker.
LENZ Therapeutics Launches VIZZ Telehealth Prescribing Option for the Treatment of Presbyopia
LENZ Therapeutics has launched a new telehealth platform for VIZZ (aceclidine ophthalmic solution) 1.44%, an eye drop for presbyopia. This platform allows patients to receive online evaluations from licensed eyecare providers, get prescriptions fulfilled by an e-pharmacy, and have VIZZ delivered directly to their homes. The initiative aims to enhance accessibility for the millions of Americans with presbyopia, especially those who may not visit an eye doctor annually, and will be promoted through a national advertising campaign featuring Sarah Jessica Parker.
LENZ Therapeutics Announces Launch of New Telehealth Prescribing Option to Accelerate Patient Access to VIZZ
LENZ Therapeutics has launched a new telehealth prescribing option for VIZZ (aceclidine ophthalmic solution) 1.44%, an eye drop for presbyopia. This platform allows patients to receive online evaluations from licensed eye care providers, prescription fulfillment, and home delivery, aiming to improve accessibility for the 128 million Americans with presbyopia. The launch coincides with a national TV advertising campaign featuring Sarah Jessica Parker to boost consumer awareness and adoption.
LENZ Therapeutics Announces Launch of New Telehealth Prescribing Option to Accelerate Patient Access to VIZZ® for the Treatment of Presbyopia
LENZ Therapeutics has launched a new telehealth prescribing option for VIZZ® (aceclidine ophthalmic solution) 1.44%, an eye drop for presbyopia. This platform, accessible via VIZZ.com, allows patients to consult with independent licensed eye care providers online, receive prescriptions through an e-pharmacy, and have the product delivered to their homes. The initiative aims to expand access to VIZZ for the estimated 128 million Americans with presbyopia, especially those who may not visit an eye doctor annually, and will be promoted through a national TV advertising campaign featuring Sarah Jessica Parker.
LENZ lets eligible patients get VIZZ online, with home delivery
LENZ Therapeutics has launched a new telehealth prescribing option for its VIZZ aceclidine ophthalmic solution, designed to treat presbyopia. This platform, accessible via VIZZ.com, connects patients with licensed eye care providers for online evaluations, e-pharmacy prescription fulfillment, and home delivery. The initiative is being promoted through a national TV and digital campaign featuring Sarah Jessica Parker, aiming to enhance awareness, access, and adoption of VIZZ among the 128 million Americans with presbyopia.
LENZ Therapeutics Launches Telehealth Access for VIZZ Alongside National TV Campaign
LENZ Therapeutics has launched telehealth accessibility for its presbyopia treatment, VIZZ (aceclidine ophthalmic solution) 1.44%, allowing patients to receive online evaluations, e-pharmacy prescription fulfillment, and home delivery. This initiative coincides with a national advertising campaign featuring Sarah Jessica Parker to boost awareness and adoption among the 128 million Americans affected by presbyopia. While this expansion improves convenience and outreach, potential negatives include reliance on independent eye care professionals for evaluations and reported adverse reactions like instillation site irritation and dim vision, which could impact consumer confidence.
LENZ - LENZ Therapeutics Inc Options
This article provides comprehensive financial data for LENZ Therapeutics Inc. (LENZ), including its last closing price, market capitalization, income, sales, and various financial ratios. It also details insider and institutional ownership, stock performance metrics, and analyst recommendations.
Director departure and audit committee change at LENZ Therapeutics (NASDAQ: LENZ)
LENZ Therapeutics announced changes to its Board of Directors and Audit Committee following the resignation of director Zach Scheiner on June 30, 2026. Scheiner's departure was not due to any dispute, and the Board subsequently reduced its size to six members. Additionally, Jeff George was appointed to the Audit Committee, which now includes Shelley Thunen, Frederic Guerard, and Jeff George.
Price to sales forward of LENZ Therapeutics, Inc. – NASDAQ:LENZ
This article focuses on the "Price to sales forward" metric for LENZ Therapeutics, Inc. (NASDAQ: LENZ). It appears to be a financial data snippet from TradingView, providing an overview of the company's stock performance. The content includes general market information and links to various TradingView features but lacks detailed financial analysis or specific numerical data for the price-to-sales forward ratio.
Price to book forward of LENZ Therapeutics, Inc. – NASDAQ:LENZ
This article provides a brief financial update on LENZ Therapeutics, Inc. (NASDAQ: LENZ), specifically focusing on its price-to-book forward ratio. The content indicates the market is currently closed, with no trades, and offers information on the company's financials, news, and other market data points accessible through TradingView.
Enterprise value to revenue forward of LENZ Therapeutics, Inc. – NASDAQ:LENZ
This article provides financial information for LENZ Therapeutics, Inc. (NASDAQ: LENZ), specifically focusing on its enterprise value to revenue forward. The content appears to be a financial snapshot from TradingView, detailing various data points and market information relevant to the company.
Price to earnings forward of LENZ Therapeutics, Inc. – NASDAQ:LENZ
This article provides the "Price to earnings forward" metric for LENZ Therapeutics, Inc. (NASDAQ: LENZ). It's presented within the context of TradingView's financial data offerings for the company. The page focuses on a specific financial data point rather than a detailed analytical report.
LENZ Therapeutics, Inc.(NasdaqGS:LENZ) added to Russell Microcap Value Benchmark Index
LENZ Therapeutics, Inc. (NasdaqGS:LENZ), a biopharmaceutical company focused on developing treatments for presbyopia, has been added to the Russell Microcap Value Benchmark Index. This news follows a period of significant activity for the company, including recent license agreements, earnings reports, and analyst rating changes. The article also provides a company profile, financial data, and analyst consensus.
LENZ Therapeutics, Inc.(NasdaqGS: LENZ) added to Russell 2000 Value Benchmark
LENZ Therapeutics, Inc. (NasdaqGS: LENZ) has been added to the Russell 2000 Value Benchmark Index. This news follows several recent updates for the biopharmaceutical company, including its addition to the Russell Microcap Value Benchmark and an exclusive licensing agreement for its VIZZ product in Australia and New Zealand. The company develops aceclidine-based eye drops for presbyopia.
LENZ Therapeutics, Inc.(NasdaqGS:LENZ) dropped from Russell Small Cap Comp Growth Benchmark
LENZ Therapeutics, Inc. (NasdaqGS:LENZ) has been removed from the Russell Small Cap Comp Growth Benchmark. This news follows a previous report that the company was also dropped from the Russell 3000 Growth Benchmark. The company, which is a pre-commercial stage biopharmaceutical firm focusing on an aceclidine-based eye drop for presbyopia, has recently seen its stock performance decline significantly.
Millennium Group reports 1.60M-share (5.1%) LENZ stake (LENZ)
Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have reported a shared voting and dispositive power over 1,603,512 shares, or 5.1%, of LENZ Therapeutics, Inc. Common Stock. This disclosure was made via a Schedule 13G filing, indicating a passive investment. The shares are held by entities managed by Millennium Management LLC and its affiliates, as detailed in a joint filing agreement.
LENZ Therapeutics, Inc. Actuals & Estimates (NASDAQ:LENZ)
This article provides an overview of LENZ Therapeutics, Inc. (NASDAQ: LENZ) stock performance, financial data, and analyst estimates. It includes current stock price, historical highs and lows, market capitalization, volatility, and upcoming earnings report details. The company's financials for the last quarter, including earnings per share and revenue, are also highlighted.
LENZ Therapeutics Eye Drug Profile Supports Blockbuster Opportunity: Analyst
LENZ Therapeutics has signed an exclusive licensing and commercialization agreement with Arrotex Pharmaceuticals for its FDA-approved eye drop therapy, VIZZ, targeting presbyopia in Australia and New Zealand. This marks LENZ's fifth such international partnership, with an analyst from William Blair highlighting its potential as a blockbuster drug due to its best-in-class profile and differentiated efficacy, despite early launch phases in the U.S.
LENZ Therapeutics, Inc. and Arrotex Pharmaceuticals Pty Ltd. Announce Exclusive License and Commercialization Agreement for VIZZ in Australia and New Zealand
LENZ Therapeutics, Inc. has announced an exclusive license and commercialization agreement with Arrotex Pharmaceuticals Pty Ltd. for its presbyopia treatment, VIZZ, in Australia and New Zealand. LENZ Therapeutics will receive an upfront payment and a significant share of gross profit from product sales, while Arrotex Pharmaceuticals gains exclusive commercialization rights for VIZZ in these regions. The agreement expands the availability of VIZZ, an aceclidine-based eye drop for near vision improvement, into new markets.
LENZ licenses presbyopia drug VIZZ to Arrotex for Australia, NZ By Investing.com
LENZ Therapeutics has granted Arrotex Pharmaceuticals exclusive rights to register and commercialize its presbyopia drug VIZZ in Australia and New Zealand. LENZ will receive an upfront payment and profit share from sales of VIZZ, a once-daily eye drop that received FDA approval in July 2025. Despite this expansion, LENZ shares are trading near their 52-week low, and analyst ratings have been adjusted due to slower-than-expected sales.
LENZ Therapeutics and Arrotex Pharmaceuticals Announce Exclusive License and Commercialization Agreement for VIZZ™ in Australia and New Zealand
LENZ Therapeutics and Arrotex Pharmaceuticals have entered into an exclusive license and commercialization agreement for VIZZ™ eye drops in Australia and New Zealand. This partnership will see Arrotex, Australia’s largest pharmaceutical company, register and commercialize VIZZ, LENZ's FDA-approved aceclidine-based eye drop for presbyopia. LENZ will receive an upfront payment and a significant profit share from product sales, expanding its global commercial footprint for this transformative presbyopia therapy.
